FDA approves Amgen and Allergan’s Kanjinti, Herceptin biosimilar

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Amgen and Allergan Kanjinti’s (trastuzumab-anns) for all approved indications of the reference product, Herceptin (trastuzumab) for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login